Comparative Effectiveness of Biomarkers to Target Cancer Treatment: Modeling Implications for Survival and Costs

about

Comparative Effectiveness of Biomarkers to Target Cancer Treatment: Modeling Implications for Survival and Costs

Item

http://www.wikidata.org/entity/Q36614650

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Comparative Effectiveness of B ...... cations for Survival and Costs

@ast

Comparative Effectiveness of B ...... cations for Survival and Costs

@en

type

Item

label

Comparative Effectiveness of B ...... cations for Survival and Costs

@ast

Comparative Effectiveness of B ...... cations for Survival and Costs

@en

prefLabel

Comparative Effectiveness of B ...... cations for Survival and Costs

@ast

Comparative Effectiveness of B ...... cations for Survival and Costs

@en

P1476

Comparative Effectiveness of B ...... cations for Survival and Costs

@en

P2093

Jeanette K Birnbaum

http://www.w3.org/2001/XMLSchema#string

Josh J Carlson

http://www.w3.org/2001/XMLSchema#string

Mark W Mason

http://www.w3.org/2001/XMLSchema#string

Ruth Etzioni

http://www.w3.org/2001/XMLSchema#string

P2860

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement

Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.

Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.

Targeting HER2: recent developments and future directions for breast cancer patients.

Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation.

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions

Breast cancer adjuvant therapy: time to consider its time-dependent effects.

The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.

The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.

P304

594-603

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0272989X15601998

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Leslie Mallinger

Foluso Ademuyiwa

P577

2015-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26304062

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

4766067

http://www.w3.org/2001/XMLSchema#string